Mandate Vinge advises Oncopeptides in connection with a directed share issue

May 11, 2020

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 1,414 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Carnegie Investment Bank AB (publ), Cowen, DNB Markets, a part of DNB Bank ASA, Jefferies International Limited and Kempen & CO N.V.

 

Oncopeptides is a clinical development pharmaceutical company focused on conducting anti‑cancer research to develop treatments for the benefit of patients. The company’s shares are admitted to trading on Nasdaq Stockholm.

 

Vinge’s team has consisted of Dain Hård Nevonen, Sofie Bjärtun, Linnéa Sellström and Hampus Olsson.

 

Sanctions round-up

Not long time ago sanctions were a rare occurrence which only involved obscure products and countries, and which were decided by the members of the United Nations Security Council. Today, the European Union and, in particular, the United States, impose sanctions and other trade restrictions with high frequency which have the potential to affect any type of transaction. Below you will find a summary of some recent developments.
December 22, 2020

EU Commission criticizes Sweden for its application of the rules on combined transports

Through a formal notice to Sweden, the European Commission has criticized the inadequate application of Directive 92/106/ECC on common rules for certain forms of combined transport of goods between Member States (the “Combined Transports Directive”). The notice mainly concerns the Swedish Transport Agency's application of the term "nearest suitable railway station"
December 11, 2020